ClinicalTrials.Veeva

Menu

The Role of Immune Semaphorins in Steatotic Liver Disease and Sepsis (SepsisFAT)

U

University Hospital for Infectious Diseases, Croatia

Status

Enrolling

Conditions

Immune Response
Steatosis of Liver
Sepsis

Treatments

Diagnostic Test: Measurement of inflammatory cytokines
Diagnostic Test: Evaluation of the degree of steatosis
Diagnostic Test: Screening for the components of metabolic syndrome
Diagnostic Test: Measurement of serum semaphorin concentrations

Study type

Observational

Funder types

Other

Identifiers

NCT06021743
UHID-08

Details and patient eligibility

About

The impact of the complex liver immunological network on sepsis outcome is largely unknown. Steatotic liver disease (SLD) is the most common chronic liver disease with prevalence of 25% in European countries. The question remains whether patients with SLD are more prone to bacterial infections and what is the impact of persistent liver inflammation to the systemic response to infection, sepsis course and outcomes. Semaphorins are a large family of secreted and membrane-bound biological response modifiers present in many organ systems that are associated with SLD and development of fibrosis, but also might regulate systemic immune responses in sepsis. This study will investigate the association of semaphorins with sepsis outcomes in patients with SLD.

Full description

The liver, with its ability to produce acute phase proteins, complement and cytokines, plays a central role in regulating inflammation. A balanced pro- and anti-inflammatory liver response results in bacterial clearance and resolution of inflammation. Steatotic liver disease (SLD) is the most common chronic liver disease associated with systemic changes in immune response. Although there are numerous immunological links between sepsis and SLD, there is a significant gap in knowledge regarding the role of SLD in sepsis. Semaphorins were recently recognized as one of the key regulators of immune responses; while some suppress immune cells activation, proliferation and production of inflammatory cytokines, others stimulate immune responses. Semaphorins were recently shown to be associated with pathogenesis of viral hepatitis, SLD and progression of fibrosis. However, their role in sepsis is unknown. The hypothesis of this project is that semaphorins are regulators of inflammation in patients with SLD that have impact on sepsis outcome.

Enrollment

160 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • 2 or more SIRS (Systemic Inflammatory Response Syndrome) criteria (1. Hyperthermia >38.3°C or Hypothermia <36°C; 2. Tachycardia >90 bpm; 3. Tachypnea >20 bpm; 3. Leukocytosis (>12,000 μL-1) or Leukopenia (<4,000 μL-1))
  • clinical suspicion of sepsis
  • enrolled within 24 hours of hospital admission

Exclusion criteria

  • no consent
  • immunosuppression
  • malignancies
  • immune diseases
  • pregnancy
  • HIV infection
  • presence of chronic liver disease
  • consumption of alcohol > 20 g/day

Trial design

160 participants in 1 patient group

Sepsis
Description:
Patients hospitalized due to the sepsis
Treatment:
Diagnostic Test: Measurement of serum semaphorin concentrations
Diagnostic Test: Measurement of inflammatory cytokines
Diagnostic Test: Evaluation of the degree of steatosis
Diagnostic Test: Screening for the components of metabolic syndrome

Trial contacts and locations

1

Loading...

Central trial contact

Nina Vrsaljko, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems